MetaCap

Cytek Biosciences (CTKB) vs Pacific Biosciences of California (PACB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cytek Biosciences (CTKB) has outperformed Pacific Biosciences of California (PACB) over the past year, gaining 4.1% versus a loss of 26.6%. Over five years, CTKB leads with a -67.8% price change compared with -93.0% for PACB. Cytek Biosciences is the larger company by market cap ($800.4 million vs $508.9 million), about 1.6 times the size, while Pacific Biosciences of California is growing revenue faster (+3.9% vs +0.5%).

Cytek Biosciences converts more of its revenue into profit, with a net margin of -33.0% versus -341.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CTKB+4.08%PACB-26.58%
+35%-10%-54%
Nov 21, 20251 yearNov 20, 2026
CTKB-68.58%PACB-93.84%
+5%-48%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CTKB versus PACB key metrics
MetricCTKBPACB
Share price$6.12$1.63
Market cap$800.40M$508.95M
1-day change-3.16%-7.39%
YTD return+21.19%-12.83%
1-year return+4.08%-26.58%
5-year return-67.82%-93.01%
Forward P/E87.43—
EPS (TTM)$-0.63$-0.42
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$201.49M$160.00M
Revenue growth (YoY)+0.52%+3.89%
Net income (latest FY)$-66.54M$-546.38M
Gross margin51.84%28.61%
Operating margin-20.04%-346.15%
Net margin-33.02%-341.47%
52-week high$6.39$3.44
52-week low$3.31$1.07
Distance from 52-week high-4.15%-52.62%
Analyst consensusbuybuy
Avg. price target upside+6.21%+68.10%
Average volume1.31M13.23M
Shares outstanding130.78M312.24M
Employees703485
SectorIndustrialsIndustrials
IndustryBiotechnology: Laboratory Analytical InstrumentsBiotechnology: Laboratory Analytical Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CTKB has outperformed PACB by 30.7 percentage points over the past year.
  • Cytek Biosciences is more profitable, keeping -33.0 cents of every revenue dollar as net income versus -341.5 cents for Pacific Biosciences of California.

About Cytek Biosciences

CTKB stock →

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems.

Industrials · Biotechnology: Laboratory Analytical Instruments · 703 employees

About Pacific Biosciences of California

PACB stock →

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.

Industrials · Biotechnology: Laboratory Analytical Instruments · 485 employees

CTKB vs PACB FAQ

Which is bigger, Cytek Biosciences or Pacific Biosciences of California?

Cytek Biosciences (CTKB) is larger, with a market capitalization of $800.40M compared with $508.95M for Pacific Biosciences of California (PACB).

Which stock has performed better over the past year, CTKB or PACB?

CTKB returned +4.08% over the past 12 months, compared with -26.58% for PACB (price return, excluding dividends). Past performance does not predict future results.

Are Cytek Biosciences and Pacific Biosciences of California in the same industry?

Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.

More comparisons